EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

Michal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, Benoit Tessoulin, Alexey Danilov, Alvaro J Alencar, Nirav N Shah, Hervé Ghesquieres, Steven Le Gouill, Wojciech Jurczak, Hongmei Han, Eunice Yuen und 4 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.01.018 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Michal Kwiatek und 15 weiteren Autor:innen. Beteiligte Einrichtung: Aidport Clinical Trials Hospital, Skorzewo, Poland. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Proto-Oncogene Proteins c-bcl-2, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: LOXO-338 is a novel, orally bioavailable small-molecule inhibitor of Bcl-2, designed to achieve selectivity for Bcl-2 over Bcl-xL, thus avoiding dose-limiting thrombocytopenia associated with Bcl-xL inhibition. This first-in-human, open-label, Phase 1 study investigated LOXO-338 in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell non-Hodgkin lymphoma (NHL) (NCT05024045). PATIENTS AND METHODS: Patients with histologically confirmed advanced B-cell malignancies who had received ≥ 2 prior therapies were enrolled in Phase 1 dose escalation (interval 3 + 3 design). LOXO-338 was administered orally as 50 to 300 mg once-daily dose until discontinuation due to progressive disease or unacceptable toxicity. The primary objective was to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose of LOXO-338. Secondary objectives included safety, tolerability, pharmacokinetics, and preliminary antitumor activity. RESULTS: In total, 27 patients with CLL/SLL (n = 10) or NHL (n = 17) were treated. No dose-limiting toxicities occurred and the MTD was not reached. Treatment-emergent adverse events occurred in 23 patients (85%); anemia (22%) and fatigue (22%) were the most prevalent. Treatment-related adverse events (TRAEs) occurred in 15% and were mostly grade 1 (11%) or 2 (4%); grade ≥ 3 or serious TRAEs were not reported. Tumor lysis syndrome was not observed. The overall response rate was 19% (95% CI: 6.3, 38.1) and disease control rate was 67% (95% CI: 46, 83.5). LOXO-338 was orally bioavailable with dose-dependent increases in exposure. CONCLUSION: LOXO-338 was well tolerated with a favorable safety profile in previously treated patients with advanced hematologic malignancies. Preliminary efficacy was observed in this heavily pretreated population supporting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsHumansMaleFemaleMiddle AgedAgedAdultAdministration, OralAged, 80 and overMaximum Tolerated DoseLeukemia, Lymphocytic, Chronic, B-CellTreatment Outcome

Stichwörter der Autor:innen

ApoptosisB-cell non–Hodgkin lymphomaBcl-xLChronic lymphocytic leukemiaSmall lymphocytic lymphoma

Substanzen

Proto-Oncogene Proteins c-bcl-2Antineoplastic Agents

Autor:innen und Institutionen

  • Aidport Clinical Trials Hospital, Skorzewo, Poland.
  • Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.
  • Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Overland Park, KS.
  • Service d'Hématologie Clinique, CHU de Nantes, Place Alexis Ricordeau, Nantes, France.
  • Toni Stephenson Lymphoma Center, City of Hope National Medical Center, Duarte, CA.
  • Department of Medicine, Division of Hematology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Kwiatek, M., Murthy, G. S. G., Hoffmann, M., Tessoulin, B., Danilov, A., Alencar, A. J., Shah, N. N., Ghesquieres, H., Le Gouill, S., Jurczak, W., Han, H., Yuen, E., Patel, V., Guo-Avrutin, Y., Pauff, J. M., & Roeker, L. E. (2025). A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.01.018

Vancouver

Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, et al. A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.01.018

BibTeX
@article{Kwiatek2025,
  author = {Kwiatek, Michal and Murthy, Guru Subramanian Guru and Hoffmann, Marc and Tessoulin, Benoit and Danilov, Alexey and Alencar, Alvaro J and Shah, Nirav N and Ghesquieres, Hervé and Le Gouill, Steven and Jurczak, Wojciech and Han, Hongmei and Yuen, Eunice and Patel, Vishalkumar and Guo-Avrutin, Yingying and Pauff, James M and Roeker, Lindsey E},
  title = {A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.01.018}
}
Kostenlos starten →